Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

4 CBD Stocks To Win Big In June

By Zacks Investment ResearchStock MarketsJun 04, 2019 07:39AM ET
www.investing.com/analysis/4-cbd-stocks-to-win-big-in-june-200428136
4 CBD Stocks To Win Big In June
By Zacks Investment Research   |  Jun 04, 2019 07:39AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Cannabis stocks since inception have fascinated investors. Prolonged trade tensions will, no doubt, affect the global economy and squeeze corporate profits. To light things up a little, weed can be legalized, opening the door to a multi-billion-dollar industry.

Medical marijuana has already been legalized in 33 states and is being exported in large amounts. Europe, in particular, is open to marijuana-based treatments, while some Asian countries have endorsed it as well.

But cannabidiol or CBD is a sensation right now. We all know that hemp got legalized in the 2018 Farm Bill, following which a slew of hemp-based commodities were sold online and in mom-and-pop stores. However, CBD was placed under the review of the FDA, which recently said that there may be real risks associated with it.

But the regulatory authority acknowledged that there is immense public interest in CBD as a wellness aid. Lest we forget, CBD is widely used in treating pain, inflammation and epilepsy.

Talking about strong demand for CBD, analysts estimated that nearly 65 million Americans have tried CBD and 63% found it effective. What’s more, CBD is a growing industry. Market research firm Brightfield projected that CBD sales in the United States alone will jump 55% to $648 million by the end of this year. In fact, they expect the U.S. hemp CBD market to reach a worth of $22 billion by 2022.

And if we consider a more conservative estimate, the numbers are still encouraging. For instance, investment firm Piper Jaffray forecasted annual U.S. hemp CBD sales close to around $15 billion by 2023.

Hence, this is the time to cash in on the hemp CBD craze. We have, thus, highlighted four CBD stocks that investors should keep an eye on this month —

GW Pharmaceuticals

GW Pharmaceuticals plc (NASDAQ:GWPH) predominantly focuses on manufacturing CBD drugs. Last year, it’s CBD drug Epidiolex was the first cure made from Cannabis sativa plant species to win approval from the FDA. The drug is primarily used to treat rare forms of epilepsy.

GW Pharmaceuticals reported higher-than-expected sales of Epidiolex during the first quarter, and the drug is also the primary reason for GW Pharmaceuticals’ share outperformance against the broader Medical - Products industry so far this year (+80.3% vs +6.8%).

GW Pharmaceuticals, by the way, has announced promising results from a phase 3 study of Epidiolex in treating another rare type of epilepsy. Meanwhile, the Zacks Consensus Estimate for its current-year earnings has increased more than 100% over the past 60 days.

Canopy Growth

Canopy Growth (NYSE:CGC) is one of the first major Canadian marijuana manufacturers to enter the U.S. hemp CBD market. The company is now expected to buy This Works, a London-based skin care company, for around $55 million. Such acquisitions will bolster its plans to sell more hemp-derived, CBD based wellness products to customers.

The company is also constructing a large-scale hemp production facility in New York state, and has secured the rights to acquire U.S. cannabis company Acreage Holdings. Notably, Constellation Brands (NYSE:STZ) has a 38% stake in Canopy Growth and is helping the company produce and market cannabis-related products.

The Zacks Consensus Estimate for its current-year earnings has risen almost 108% over the past 60 days. The company has easily outdone the broader Medical - Products industry on a year-to-date basis (+44.1% vs +6.8%).

Aurora Cannabis

With a greater number of people using CBD to cure a variety of ailments, demand for cannabis has increased by leaps and bounds. And this is how Aurora Cannabis (TSX:ACB) will benefit immeasurably. After all, Aurora Cannabis is currently the largest producer of cannabis. It is expected to produce more than 625,000 kilograms of cannabis annually by 2020, thanks to its acquisitions of MedReleaf, CanniMed and ICC Labs, to name a few.

Being the largest producer of cannabis, Aurora Cannabis enjoys a competitive advantage over small-scale producers. The company can easily generate higher profit margins, thanks to its larger revenue base.

The Zacks Consensus Estimate for its next-year earnings has increased 3% over the past 60 days. The company has performed better than the broader Medical - Products industry on a year-to-date basis (+44.4% vs +6.8%).

Hexo

If you are late into the cannabis game, you might be reluctant to invest in the top-tier names, as they might be pricey. So, beginners may consider Hexo (TSX:HEXO) . Yes, the company may not be known to all, but it’s underdog status actually helped its share prices advance 18.8% so far this year, beating the broader Medical - Products industry’s rise of 6.8%.

That said, Hexo’s share price has more upside left. After all, Hexo has tied up with alcoholic beverage-maker Molson Coors Brewing (TAP) to produce CBD filled, non-alcoholic drinks.

Nonetheless, while GW Pharmaceuticals flaunts a Zacks Rank #2 (Buy), Canopy Growth, Aurora Cannabis and Hexo have a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report

Canopy Growth Corporation (CGC): Free Stock Analysis Report

HEXO Corp. (HEXO): Free Stock Analysis Report

Aurora Cannabis Inc. (ACB): Free Stock Analysis Report

Original post

Zacks Investment Research
4 CBD Stocks To Win Big In June
 

Related Articles

4 CBD Stocks To Win Big In June

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email